Page 14 - Pharma Sector

Indian pharma market registers over 8% growth in January 2025: Pharmarack

Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, and 6.9 per cent, respectively, driving overall IPM growth

Lilly forecasts 2025 profit above estimates on weight-loss drug strength

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter

Zydus Life up 3% on mixed Q3, mcap tops Rs 1 trn; analysts split on outlook

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which led to a PAT beat, analysts said

ICMR initiates process of vaccine development against avian influenza

The ICMR has initiated the process of development of an ingenious human vaccine candidate against highly-pathogenic avian influenza (H5N1). The Indian Council of Medical Research (ICMR) has invited expression of interest from the eligible organisations, companies, manufacturers for joint collaboration in research and development for development of human vaccine candidate against H5N1. The avian influenza H5N1, a highly pathogenic strain of bird flu, continues to pose a significant threat to animal and human health in India. Recent outbreaks in 2021, 2023 and 2024 have been reported in several states, primarily affecting poultry and wild birds, the expression of interest document said. These outbreaks have caused significant economic losses in the poultry industry and raised public health concerns due to the virus's zoonotic potential, it said. The document stated that avian influenza H5N1 virus poses a grave public health risk because of its high mortality rate and its potential t

Pfizer beats profit estimates on heart disease drug, Covid vaccine sales

Pfizer is facing investor pressure to show that its recent acquisitions and investments can bring in returns

3 firms divest 6.8% stake in Onesource Specialty Pharma for Rs 1,202 crore

Three entities, including two promoters of Onesource Specialty Pharma, on Friday divested a 6.8 per cent stake in the company for Rs 1,202 crore through open market transactions. Tenshi Pharmaceuticals (Promoter) and Pronomz Ventures LLP (Promoter Group) and Medella Holdings Pte Ltd were the entities who have offloaded 77.66 lakh shares or 6.8 per cent stake in Bengaluru-based Onesource Specialty Pharma, as per the bulk deal data available on the NSE. The shares were disposed of in the price range of Rs 1,545-1,552.90 apiece, taking the combined value to Rs 1,202.23 crore. The promoters of the company divested a 3.4 per cent stake in the firm. After the latest transaction, the combined shareholding of promoter holding in Onesource Specialty Pharma has come down to 34.36 per cent from 37.77 per cent and Medella Holdings stake has declined to 0.8 per cent from 4.17 per cent. Meanwhile, Motilal Oswal Mutual Fund and CPT Research & Mgmt Co T/A CPT World Investors acquired 21.95 lakh .

Biocon Biologics plans IPO for biosimilars business by Mar 2026: CEO

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public

Ajanta Pharma Q3 results: Net profit increases 11% to Rs 233 crore

Ajanta Pharma on Thursday said its consolidated profit after tax increased by 11 per cent on-year to Rs 233 crore for the third quarter ended December 31, 2024. The drug firm had reported a profit after tax (PAT) of Rs 210 crore in the October-December period of last fiscal. Revenue from operations stood at Rs 1,146 crore in the third quarter compared to Rs 1,105 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. Shares of the company settled 1.64 per cent higher at Rs 2,670.70 apiece on the BSE.

Cigna falls short of Q4 profit estimates due to higher medical costs

The plan, called "stop-loss insurance", entails the insurer covering for employers' self-funded plans when their costs surpass a certain threshold due to catastrophic or unexpected medical claims

Dr Lal Path Labs Q3FY25 results: Net profit jumps 19% to Rs 96.7 crore

The company's consolidated net profit rose to Rs 96.7 crore ($11.2 million) in the three months to Dec. 31, from Rs 81.3 crore a year earlier, but fell short of analysts' estimate of Rs 97.69 crore

Cipla Q3 Preview: Supply disruptions, market share loss to weigh on topline

Cipla Q3 Preview: India's third largest pharmaceutical company, Cipla, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Tuesday, January 28

Flipkart has ended its partnership with us: Medicine e-tailer Sastasundar

Medicine e-tailer Sastasundar on Tuesday said that e-commerce giant Flipkart has ended its partnership in the online pharmacy and healthcare space with it. The Kolkata-based entity also said it has reclaimed its brand's intellectual property rights (IPRs). The Walmart-owned Flipkart had acquired a 75 per cent stake in Sastasundar Marketplace in 2021. An e-mail sent to Flipkart on the development did not elicit any response. "The deal with Flipkart is over and we got back all the intellectual property rights of the Sastasundar brand from it. Now, we will launch our app. In 2021, we had sold a 75 per cent stake in Sastasundar Marketplace Ltd for around Rs 750 crore to Flipkart," Sastasundar Group chairman B L Mittal told PTI. This reclaim transaction did not attract any material investment, he said. Holding company Sastasundar Ventures has re-acquired the brand's IPRs and non-compete rights from Flipkart Health+ through its newly-formed subsidiary, Sastasundar Healthtech Ltd, he ..

Doctors may face suspension in NMC probe over pharma-sponsored trips

This was in violation of the UCPMP rules, which regulate interactions between pharmaceutical companies and HCPs and prohibit foreign trips, gifts, and inducements as unethical marketing practices

Union Budget 2025-26: Customs duty hike likely on key pharma, RE products

Key components in the renewable energy industry such as special bearings, gearboxes, yaw components, wind turbine controllers are currently subjected to a concessional customs duty of 5 per cent

Senores Pharmaceuticals races 17% on robust Q3; profit more than doubles

The rise in Senores Pharmaceuticals share came after the company's strong show in the December quarter (Q3FY25) results

Indoco Remedies drops 4% on weak Q3 performance; revenue falls 11% YoY

Indoco Remedies share dropped after the company reported a weak set of numbers in the December quarter of financial year 2025 (Q3FY25)

Venus Remedies share price surges 12% on renewal of EU GMP certification

The rise in Venus Remedies share price came after the company announced the renewal of its European GMP certification by Infarmed, the National Authority of Medicines and Health Products in Portugal

Glenmark Pharma share rises 2% as unit launches blood clotting drug

The uptick in Glenmark Pharmaceuticals share price came after the company announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules

French firm Roquette seeks CCI's clearance for IFF Pharma's biz acquisition

French plant-based ingredient producer Roquette Frres has sought fair trade regulator CCI's approval for the proposed acquisition of the pharma solutions business and certain product lines of International Flavors & Fragrances Inc (IFF). Roquette Frres S.A. is a family-owned French firm active in the production and sale of plant-based ingredients, excipients, and plant proteins for various applications. It has operations in India through several subsidiaries, like Crest Cellulose, Sethness-Roquette India and Roquette India. "The proposed transaction refers to the proposed acquisition by Roquette of the pharma solutions business and certain product lines of the Nourish business (ie, collectively the target business) of IFF by way of Roquette's purchase of equity interest in certain IFF entities that collectively house / are proposed to house the target business," said a notice filed with the CCI on January 16. The target business primarily comprises the operations, and activities ..

Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS